Á¦7Â÷ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ °æÀÎÁöȸ ½ÉÆ÷Áö¾ö : 2023-09-09
±³À°ÀÏÀÚ : 2023-09-09
±³À°Àå¼Ò : °¡Å縯°üµ¿´ëÇб³ ±¹Á¦¼º¸ðº´¿ø, ¸¶¸®¾ÆȦ(3F)
±³À°ÁÖÁ¦ : Á¦7Â÷ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ °æÀÎÁöȸ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : °æÀÎÁöȸ
´ã´çÀÚ : Á¶¿¹¸®
¿¬¶ôó : 02-582-8222
À̸ÞÀÏ : yehc@kscvi.org
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ÀÎõ±¤¿ª½Ã
±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í -Á¤È¸¿ø ¹«·á µî·Ï -Àü¹®ÀÇ/°³¿øÀÇ/ÀϹÝÀÇ: 60,000 -ÀüÀÓÀÇ/Àü°øÀÇ: 30,000 -°£È£»ç/ÀÇ·á±â»ç/ÀÇ´ë»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/ÀÓ»óº´¸®»ç/Àǹ«±â·Ï»ç: 20,000 -»ê¾÷ü/±âŸ: 120,000 * ÇöÀåµî·Ï¸¸ °¡´ÉÇÕ´Ï´Ù.
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 09:00~09:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) The Anterograde Approach for CTO(Chronic Total Occlusion) À̿뱸(ÇѾçÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 09:10~09:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) The Retrograde Approach for CTO(Chronic Total Occlusion) ¼Á¸(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 09:20~09:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Novel Devices for CTO(Chronic Total Occlusion) including Catheters and Wires ¼¿ë¼º(¸íÁöº´¿ø)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 09:30~09:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) The Role of DCB(Drug-coated Balloon) for CTO(Chronic Total Occlusion) ±è¼±¿ø(°í·ÁÀÇ´ë)
Åä·Ð 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 09:40~10:00 Discussion ()
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 10:00~10:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Step-by-Step: When and How to Deploy Two Stents in a Bifurcation Lesion À念¿ì(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 10:10~10:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Step-by-Step: Rotablator Use in Severely Calcified Lesions ¹ÚÇüº¹(°¡Å縯°üµ¿ÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 10:20~10:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Step-by-step: How to Treat Lesions with Stent Restenosis or Thrombosis À̽·ü(Â÷ÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 10:30~10:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Reimbursement Rejection Experiences in CHIP PCI(High Risk Percutaneous Coronary Intervention) ÀÌÇöÁ¾(ºÎõ¼¼Á¾º´¿ø)
Åä·Ð 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 10:40~11:00 Discussion ()
ÈÞ½Ä 09¿ù 09ÀÏ 11:00~11:10 Coffee Break ()
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 11:10~11:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Vulnerable Plaque Identification by Imaging Modality ¹ÚÁ¾°ü(±¹¹Î°Ç°º¸Çè Àϻ꺴¿ø)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 11:20~11:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Intravascular Imaging–Guided Complex PCI(Percutaneous Coronary Intervention), lesson from RENOVATE Trial ÀÌÁÖ¸í(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 11:30~11:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Angiography-based FFR(Fractional Flow Reserve): From Clinical Evidence to Daily Practice ±âÀ¯Á¤(À»ÁöÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 11:40~11:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Non Hyperemic Pressure Ratio(NHPR) Guided PCI(Percutaneous Coronary Intervention) Àü±âÇö(¼¿ïÀÇ´ë)
Åä·Ð 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 11:50~12:10 Discussion ()
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 12:10~12:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) How to Apply Non-Hyperemic Indices in Our Practice ÀÌÇöÁ¾(ºÎõ¼¼Á¾º´¿ø)
±âŸ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 12:20~12:35 ³»°¡ °É¾î¿Â ±æ Àå¾ç¼ö(Â÷ÀÇ´ë)
Åä·Ð 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 12:35~12:45 Discussion ()
±âŸ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 12:45~12:55 °æÀÎÁöȸ ÃÑȸ ()
½Ä»ç 09¿ù 09ÀÏ 12:55~13:40 Lunch Break ()
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 13:40~13:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Patients Selection for Protected PCI(Percutaneous Coronary Intervention): Who Benfit the Most? °ø¹Î±Ô(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 13:50~14:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) IABP(Intra-aortic Balloon Pump): Clinical Evidence in High Risk PCI(Percutaneous Coronary Intervention) ±èÁ¦»ó(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 14:00~14:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) VA-ECMO(Veno-Arterial Extracorporeal membrane oxygenation): Clinical Evidence in High Risk PCI(Percutaneous Coronary Intervention) Á¶Çü¿ø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 14:10~14:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Impella: Clinical Evidence in High Risk PCI(Percutaneous Coronary Intervention) ÀåÁö¿ë(±¹¹Î°Ç°º¸Çè Àϻ꺴¿ø)
Åä·Ð 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 14:20~14:40 Discussion ()
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 14:40~14:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) My Wire Selection and Escalation Strategies in CLTI(Chronic Limb-Threatening Ischemia) ¹ÚÇö¿ì(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 14:50~15:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Vessel Prep in Severe Calcification ¹Ú»óµ·(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 15:00~15:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Drug Delivery and Outcomes in Calcified Lesions ±è¼¼ÈÆ(ÀÎõ¼¼Á¾º´¿ø)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 15:10~15:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Endovascular Repair of Chronic Type B Aortic Dissection °¼¼ÈÆ(Â÷ÀÇ´ë)
Åä·Ð 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 15:20~15:40 Discussion ()
ÈÞ½Ä 09¿ù 09ÀÏ 15:40~15:50 Coffee Break ()
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 15:50~16:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Valve-in-valve TAVR(Transcatheter Aortic Valve Replacement) ¹ÚÇÏ¿í(ºÎõ¼¼Á¾º´¿ø)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 16:00~16:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Expanding Indication of TAVR(Transcatheter Aortic Valve Replacement) ¹®À翬(Â÷ÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 16:10~16:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Novel Trends in PFO(Patent Foramen Ovale) ÀÌ»ó¿±(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 16:20~16:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) USE of ICE(Intracardiac echocardiography) in Structural Heart Disease °¿õö(°¡ÃµÀÇ´ë)
Åä·Ð 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 16:30~16:50 Discussion ()
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 16:50~17:05 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Relapsed NSTEMI due to Acute Gastrointestinal Bleeding after NSTEMI ¿À½Â¿í(°¡Å縯°üµ¿ÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 17:05~17:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) My First Case of Retrograde CTO(Chronic Total Occlusion) PCI(Percutaneous Coronary Intervention) ¹Î´Ù´Ï¿¤(±ºÆ÷Áö»ùº´¿ø)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 17:20~17:35 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Cases of Coronary Perforation ±è»óÈÆ(Â÷ÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 17:35~17:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Acute Myocardial Infarction Patient with Severe Thrombocytopenia ÃÖ¼ºÈ¯(ÀÎÇÏÀÇ´ë)